The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2021

Feng-Hua Wang, Xiao-Tian Zhang, Yuan-Fang Li, Lei Tang, Xiu-Juan Qu, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Hong Qiu, Chang Wang, Miao-Zhen Qiu, Mu-Yan Cai, Qi Wu, Hao Liu, Wen-Long Guan, Ai-Ping Zhou, Yu-Jing Zhang, Tian-Shu Liu, Feng Bi, Xiang-Lin Yuan, Sheng-Xiang Rao, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Guo-Xin Li, Jia-Fu Ji, Zhi-Wei Zhou, Han Liang, Yan-Qiao Zhang, Jing Jin, Lin Shen, Jin Li, Rui-Hua Xu, Feng-Hua Wang, Xiao-Tian Zhang, Yuan-Fang Li, Lei Tang, Xiu-Juan Qu, Jie-Er Ying, Jun Zhang, Ling-Yu Sun, Rong-Bo Lin, Hong Qiu, Chang Wang, Miao-Zhen Qiu, Mu-Yan Cai, Qi Wu, Hao Liu, Wen-Long Guan, Ai-Ping Zhou, Yu-Jing Zhang, Tian-Shu Liu, Feng Bi, Xiang-Lin Yuan, Sheng-Xiang Rao, Yan Xin, Wei-Qi Sheng, Hui-Mian Xu, Guo-Xin Li, Jia-Fu Ji, Zhi-Wei Zhou, Han Liang, Yan-Qiao Zhang, Jing Jin, Lin Shen, Jin Li, Rui-Hua Xu

Abstract

There exist differences in the epidemiological characteristics, clinicopathological features, tumor biological characteristics, treatment patterns, and drug selections between gastric cancer patients from the Eastern and Western countries. The Chinese Society of Clinical Oncology (CSCO) has organized a panel of senior experts specializing in all sub-specialties of gastric cancer to compile a clinical guideline for the diagnosis and treatment of gastric cancer since 2016 and renews it annually. Taking into account regional differences, giving full consideration to the accessibility of diagnosis and treatment resources, these experts have conducted expert consensus judgment on relevant evidence and made various grades of recommendations for the clinical diagnosis and treatment of gastric cancer to reflect the value of cancer treatment and meeting health economic indexes in China. The 2021 CSCO Clinical Practice Guidelines for Gastric Cancer covers the diagnosis, treatment, follow-up, and screening of gastric cancer. Based on the 2020 version of the CSCO Chinese Gastric Cancer guidelines, this updated guideline integrates the results of major clinical studies from China and overseas for the past year, focused on the inclusion of research data from the Chinese population for more personalized and clinically relevant recommendations. For the comprehensive treatment of non-metastatic gastric cancer, attentions were paid to neoadjuvant treatment. The value of perioperative chemotherapy is gradually becoming clearer and its recommendation level has been updated. For the comprehensive treatment of metastatic gastric cancer, recommendations for immunotherapy were included, and immune checkpoint inhibitors from third-line to the first-line of treatment for different patient groups with detailed notes are provided.

Keywords: Chinese Society of Clinical Oncology (CSCO); adjuvant; chemotherapy; diagnosis; gastric cancer; immunotherapy; neoadjuvant; radiotherapy; surgery; targeted therapy.

Conflict of interest statement

The authors declare that they have no competing interests.

© 2021 The Authors. Cancer Communications published by John Wiley & Sons Australia, Ltd. on behalf of Sun Yat-sen University Cancer Center.

References

    1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, Bray F.Global Cancer Statistics 2020.GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209–49.
    1. He Y, Wang Y, Luan F, Yu Z, Feng H, Chen B, Chen W. Chinese and global burdens of gastric cancer from 1990 to 2019. Cancer Med 2021;10(10):3461–73.
    1. Cao W, Chen HD, Yu YW, Li N, Chen WQ. Changing profiles of cancer burden worldwide and in China: a secondary analysis of the global cancer statistics 2020. Chin Med J. 2021;134(7):783–91.
    1. Seevaratnam R, Cardoso R, McGregor C, Lourenco L, Mahar A, Sutradhar R, et al. How useful is preoperative imaging for tumor, node, metastasis (TNM) staging of gastric cancer? A meta‐analysis. Gastric Cancer. 2012;15(1):S3–18.
    1. Amin MB, Greene FL, Edge SB, Compton CC, Gershenwald JE, Brookland RK, et al. AJCC Cancer Staging Manual, 8th ed. Springer, New York: 2017.
    1. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R. Association of Upper Gastrointestinal Surgeons of Great B, Ireland tBSoG, the British Association of Surgical O: Guidelines for the management of oesophageal and gastric cancer. Gut. 2011;60(11):1449–72.
    1. Dong L, Neuzil J. Targeting mitochondria as an anticancer strategy. Cancer Commun. 2019;39(1):63.
    1. Mocellin S, Pasquali S. Diagnostic accuracy of endoscopic ultrasonography (EUS) for the preoperative locoregional staging of primary gastric cancer. Cochrane Database Syst Rev. 2015;(2):CD009944.
    1. Kim YK, Lee MW, Lee WJ, Kim SH, Rhim H, Lim JH et al. Diagnostic accuracy and sensitivity of diffusion‐weighted and of gadoxetic acid‐enhanced 3‐T MR imaging alone or in combination in the detection of small liver metastasis (</= 1.5 cm in diameter). Invest Radiol. 2012;47(3):159–66.
    1. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009;45(2):228–47.
    1. Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, et al. iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. Lancet Oncol. 2017;18(3):e143‐e152.
    1. Wang ZC, Wang C, Ding Y, Ji Y, Zeng MS, Rao SX.CT volumetry can potentially predict the local stage for gastric cancer after chemotherapy. Diagn Interv Radiol. 2017;23(4):257–62.
    1. Giganti F, De Cobelli F, Canevari C, Orsenigo E, Gallivanone F, Esposito A, et al. Response to chemotherapy in gastric adenocarcinoma with diffusion‐weighted MRI and (18) F‐FDG‐PET/CT: correlation of apparent diffusion coefficient and partial volume corrected standardized uptake value with histological tumor regression grade. J Magn Reson Imaging. 2014;40(5):1147–57.
    1. Tang L, Li ZY, Li ZW, Zhang XP, Li YL, Li XT, et al. Evaluating the response of gastric carcinomas to neoadjuvant chemotherapy using iodine concentration on spectral CT: a comparison with pathological regression. Clin Radiol. 2015;. 70(11):1198–1204.
    1. Jiang Y, Jin C, Yu H, Wu J, Chen C, Yuan Q, et al. Development and Validation of a Deep Learning CT Signature to Predict Survival and Chemotherapy Benefit in Gastric Cancer: A Multicenter, Retrospective Study. Ann Surg. 2020.
    1. Xu G, Zhang W, Lv Y, Zhang B, Sun Q, Ling T, et al. Risk factors for under‐diagnosis of gastric intraepithelial neoplasia and early gastric carcinoma in endoscopic forceps biopsy in comparison with endoscopic submucosal dissection in Chinese patients. Surg Endosc. 2016;30(7):2716–22.
    1. Zhou PH, Schumacher B, Yao LQ, Xu MD, Nordmann T, Cai MY, et al. Conventional vs. waterjet‐assisted endoscopic submucosal dissection in early gastric cancer: a randomized controlled trial. Endoscopy. 2014;46(10):836–43.
    1. Bosman FT, Carneiro F, Hruban RH, Theise ND. WHO classification of tumours of the digestive system. In: 4th edn. France: IARC Press, 2010.
    1. Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P, et al. The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019;76.
    1. Sun Q, Fan XS, Huang Q. Suggestions on the pathological standardization of endoscopic mucosal dissection specimens for early proximal gastric cancer and precancerous lesions (Chinese). Zhonghua Xiaohua Neijing Zazhi 2016;33(9):585–88.
    1. Lauren P. The Two Histological Main Types of Gastric Carcinoma: Diffuse and So‐Called Intestinal‐Type Carcinoma. An Attempt at a Histo‐Clinical Classification. Acta Pathol Microbiol Scand 1965;64:31‐49.
    1. Ajani J, D'Amico T, Baggstrom M, Bentrem D, Chao J, Das P, et al. Gastric Cancer (Version 1, 2020). NCCN Clinical Practice Guidelines in Oncology. In; 2020.
    1. Xue WC, Fan XS, Meng G. Expert Committee Consensus. Selection of immunohistochemical markers for gastric cancer (2014) (Chinese). Linchuang yu Shiyan Binglixue Zazhi. 2014;000(009):951–3.
    1. Expert Committee on Safety Management of Anti‐neoplastic Drugs of Chinese Society of Clinical Oncology, Society of Gastric Cancer of Chinese Anti‐Cancer Association, Society of Pathology of Chinese Anti‐Cancer Association . Consensus of Chinese experts on molecular targeted therapy for HER2 positive advanced gastric cancer (2016) (Chinese). Linchuang Zhongliuxue Zazhi. 2016;21(9):831–9.
    1. Sheng WQ, Huang D, Ying JM, Lu N, Wu HM, Liu YH, et al. Du X: HER2 status in gastric cancers: a retrospective analysis from four Chinese representative clinical centers and assessment of its prognostic significance. Ann Oncol. 2013;24(9):2360–4.
    1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2‐positive advanced gastric or gastro‐oesophageal junction cancer (ToGA): a phase 3, open‐label, randomised controlled trial. Lancet 2010;376(9742):687–97.
    1. Qiu MZ, Li Q, Wang ZQ, Liu TS, Liu Q, Wei XL, et al. HER2‐positive patients receiving trastuzumab treatment have a comparable prognosis with HER2‐negative advanced gastric cancer patients: a prospective cohort observation. Int J Cancer. 2014;134(10):2468–77.
    1. Wang DS, Liu ZX, Lu YX, Bao H, Wu X, Zeng ZL, et al. Liquid biopsies to track trastuzumab resistance in metastatic HER2‐positive gastric cancer. Gut. 2019;68(7):1152–61.
    1. Wang H, Li B, Liu Z, Gong J, Shao L, Ren J, et al. HER2 copy number of circulating tumour DNA functions as a biomarker to predict and monitor trastuzumab efficacy in advanced gastric cancer. Eur J Cancer. 2018;88:92–100.
    1. Expert Committe Consensus . Guidelines for HER2 detection in gastric cancer (2016) (Chinese). Zhonghua Binglixue Zazhi. 2016;45 (8):528–32.
    1. Shitara K, Ozguroglu M, Bang YJ, Di Bartolomeo M, Mandala M, Ryu MH, et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro‐oesophageal junction cancer (KEYNOTE‐061): a randomised, open‐label, controlled, phase 3 trial. Lancet. 2018;392(10142):123–33.
    1. Gotoda T. Endoscopic resection of early gastric cancer. Gastric Cancer. 2007;10(1):1–11.
    1. Hasuike N, Ono H, Boku N, Mizusawa J, Takizawa K, Fukuda H, et al. A non‐randomized confirmatory trial of an expanded indication for endoscopic submucosal dissection for intestinal‐type gastric cancer (cT1a): the Japan Clinical Oncology Group study (JCOG0607). Gastric Cancer. 2018;21(1):114–23.
    1. Japanese gastric cancer treatment guidelines 2018 (5th edition). Gastric Cancer. 2021;24(1):1–21.
    1. Abdelfatah MM, Barakat M, Lee H, Kim JJ, Uedo N, Grimm I, Othman MO. The incidence of lymph node metastasis in early gastric cancer according to the expanded criteria in comparison with the absolute criteria of the Japanese Gastric Cancer Association: a systematic review of the literature and meta‐analysis. Gastrointest Endosc. 2018, 87(2):338–47.
    1. Hatta W, Gotoda T, Oyama T, Kawata N, Takahashi A, Yoshifuku Y, et al. A Scoring System to Stratify Curability after Endoscopic Submucosal Dissection for Early Gastric Cancer: “eCura system”. Am J Gastroenterol. 2017;112(6):874–81.
    1. National Health and Family Planning Commission of the People's Republic of China. Guidelines for standardized diagnosis and treatment of gastric cancer (trial implementation) (Chinese). Manxingbingxue Zazhi. 2013(10):47–51.
    1. Japanese Gastric Cancer Association . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1–19.
    1. Sasako M, Sano T, Yamamoto S, Sairenji M, Arai K, Kinoshita T, et al. Left thoracoabdominal approach versus abdominal‐transhiatal approach for gastric cancer of the cardia or subcardia: a randomised controlled trial. Lancet Oncol. 2006;7(8):644–51.
    1. Biondi A, D'Ugo D, Cananzi FC, Papa V, Borasi A, Sicoli F, et al. Does a minimum number of 16 retrieved nodes affect survival in curatively resected gastric cancer?. Eur J Surg Oncol. 2015;41(6):779–86.
    1. Zhang CH, Wu AW, Li ZY, Zhang LH, Bu ZD, Wu XJ, et al. Analysis of splenic hilar lymph node metastasis in advanced gastric cancer and dissection techniques (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14(8):589–92.
    1. Sasada S, Ninomiya M, Nishizaki M, Harano M, Ojima Y, Matsukawa H, et al. Frequency of lymph node metastasis to the splenic hilus and effect of splenectomy in proximal gastric cancer. Anticancer Res. 2009, 29(8):3347–51.
    1. Aoyagi K, Kouhuji K, Miyagi M, Imaizumi T, Kizaki J, Shirouzu K.: Prognosis of metastatic splenic hilum lymph node in patients with gastric cancer after total gastrectomy and splenectomy. World J Hepatol. 2010;2(2):81–6.
    1. Sano T, Sasako M, Mizusawa J, Yamamoto S, Katai H, Yoshikawa T, et al. Randomized Controlled Trial to Evaluate Splenectomy in Total Gastrectomy for Proximal Gastric Carcinoma. Ann Surg. 2017;265(2):277–83.
    1. Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer. 2011;14(2):101–12.
    1. Jiao X, Liang H, Deng J, Wang L, Liu H, Liang Y. Analysis of risk factors for station 14v lymph node metastasis in advanced gastric cancer (Chinese). Zhonghua Xiaohua Waike Zazhi. 2014;13(1):30–3.
    1. Liang YX, Liang H, Ding XW, Wang XN, Wu LL, Liu HG, et al. Significance of station 14v lymph node dissection for patients with advanced gastric cancer undergoing D2 lymphadenectomy (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2013;16(7):632–6.
    1. Eom BW, Joo J, Kim YW, Reim D, Park JY, Yoon HM, et al. Improved survival after adding dissection of the superior mesenteric vein lymph node (14v) to standard D2 gastrectomy for advanced distal gastric cancer. Surgery 2014;155(3):408–16.
    1. Shen DF, Chen DW, Quan ZW, Dong P, Wang XF, Xu HZ, et al. Dissection of No. 13 lymph node in radical gastrectomy for gastric carcinoma. World J Gastroenterol. 2008;14(6):936–8.
    1. Eom BW, Joo J, Kim YW, Park B, Park JY, Yoon HM, et al. Is there any role of additional retropancreatic lymph node dissection on D2 gastrectomy for advanced gastric cancer? Ann Surg Oncol. 2013;20(8):2669–75.
    1. Eto K, Hiki N, Kumagai K, Shoji Y, Tsuda Y, Kano Y, et al. Prophylactic effect of neoadjuvant chemotherapy in gastric cancer patients with postoperative complications. Gastric Cancer. 2018;. 21(4):703–9.
    1. Sasako M, Sano T, Yamamoto S, Kurokawa Y, Nashimoto A, Kurita A, et al. D2 lymphadenectomy alone or with para‐aortic nodal dissection for gastric cancer. N Engl J Med. 2008;359(5):453–62.
    1. Katai H, Mizusawa J, Katayama H, Morita S, Yamada T, Bando E, et al. Survival outcomes after laparoscopy‐assisted distal gastrectomy versus open distal gastrectomy with nodal dissection for clinical stage IA or IB gastric cancer (JCOG0912): a multicentre, non‐inferiority, phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol. 2020;5(2):142–51.
    1. Kim HH, Han SU, Kim MC, Kim W, Lee HJ, Ryu SW, et al. Effect of Laparoscopic Distal Gastrectomy vs Open Distal Gastrectomy on Long‐term Survival Among Patients With Stage I Gastric Cancer: The KLASS‐01 Randomized Clinical Trial. JAMA Oncol. 2019;5(4):506–13.
    1. Hyung WJ, Yang HK, Han SU, Lee YJ, Park JM, Kim JJ, et al. A feasibility study of laparoscopic total gastrectomy for clinical stage I gastric cancer: a prospective multi‐center phase II clinical trial, KLASS 03. Gastric Cancer. 2019;22(1):214–22.
    1. Katai H, Mizusawa J, Katayama H, Kunisaki C, Sakuramoto S, Inaki N, et al. Single‐arm confirmatory trial of laparoscopy‐assisted total or proximal gastrectomy with nodal dissection for clinical stage I gastric cancer: Japan Clinical Oncology Group study JCOG1401. Gastric Cancer. 2019;22(5):999–1008.
    1. Liu F, Huang C, Xu Z, Su X, Zhao G, Ye J, et al. Morbidity and Mortality of Laparoscopic vs Open Total Gastrectomy for Clinical Stage I Gastric Cancer: The CLASS02 Multicenter Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1590–7.
    1. Yu J, Huang C, Sun Y, Su X, Cao H, Hu J, et al. Effect of Laparoscopic vs Open Distal Gastrectomy on 3‐Year Disease‐Free Survival in Patients With Locally Advanced Gastric Cancer: The CLASS‐01 Randomized Clinical Trial. JAMA. 2019;321(20):1983–92.
    1. Hyung WJ, Yang HK, Park YK, Lee HJ, An JY, Kim W, et al. Long‐Term Outcomes of Laparoscopic Distal Gastrectomy for Locally Advanced Gastric Cancer: The KLASS‐02‐RCT Randomized Clinical Trial. J Clin Oncol. 2020;38(28):3304–13.
    1. Li Z, Shan F, Ying X, Zhang Y, E J‐E, Wang Y, et al. Assessment of Laparoscopic Distal Gastrectomy After Neoadjuvant Chemotherapy for Locally Advanced Gastric Cancer: A Randomized Clinical Trial. JAMA Surg. 2019;154(12):1093–1101.
    1. Chen QY, Xie JW, Zhong Q, Wang JB, Lin JX, Lu J, et al. Safety and Efficacy of Indocyanine Green Tracer‐Guided Lymph Node Dissection During Laparoscopic Radical Gastrectomy in Patients With Gastric Cancer: A Randomized Clinical Trial. JAMA Surg. 2020;155(4):300–11.
    1. Shin HJ, Son SY, Wang B, Roh CK, Hur H, Han SU.: Long‐term Comparison of Robotic and Laparoscopic Gastrectomy for Gastric Cancer: A Propensity Score‐weighted Analysis of 2084 Consecutive Patients. Ann Surg. 2020.
    1. Lu J, Zheng CH, Xu BB, Xie JW, Wang JB, Lin JX, et al. Assessment of Robotic Versus Laparoscopic Distal Gastrectomy for Gastric Cancer: A Randomized Controlled Trial. Ann Surg. 2021;273(5):858–67.
    1. Kang KC, Cho GS, Han SU, Kim W, Kim HH, Kim MC, et al. Comparison of Billroth I and Billroth II reconstructions after laparoscopy‐assisted distal gastrectomy: a retrospective analysis of large‐scale multicenter results from Korea. Surg Endosc. 2011;25(6):1953–61.
    1. Shiraishi N, Hirose R, Morimoto A, Kawano K, Adachi Y, Kitano S. Gastric tube reconstruction prevented esophageal reflux after proximal gastrectomy. Gastric Cancer. 1998;1(1):78–9.
    1. Kim HH, Han SU, Kim MC, Hyung WJ, Kim W, Lee HJ, et al. Long‐term results of laparoscopic gastrectomy for gastric cancer: a large‐scale case‐control and case‐matched Korean multicenter study. J Clin Oncol. 2014;32(7):627–33.
    1. Nunobe S, Okaro A, Sasako M, Saka M, Fukagawa T, Katai H, et al. Billroth 1 versus Roux‐en‐Y reconstructions: a quality‐of‐life survey at 5 years. Int J Clin Oncol. 2007;12(6):433–9.
    1. Liang H. Visual Lectures on Operation For Gastric Cancer (Chinese), May 1, 2013 edn: Tianjin Science and Technology Translation Publishing Co., Ltd; 2013.
    1. Fein M, Fuchs KH, Thalheimer A, Freys SM, Heimbucher J, Thiede A. Long‐term benefits of Roux‐en‐Y pouch reconstruction after total gastrectomy: a randomized trial. Ann Surg. 2008;247(5):759–65.
    1. Bang YJ, Kim YW, Yang HK, Chung HC, Park YK, Lee KH, et al. Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open‐label, randomised controlled trial. Lancet. 2012;379(9813):315–21.
    1. Lee J, Lim DH, Kim S, Park SH, Park JO, Park YS, et al. Phase III trial comparing capecitabine plus cisplatin versus capecitabine plus cisplatin with concurrent capecitabine radiotherapy in completely resected gastric cancer with D2 lymph node dissection: the ARTIST trial. J Clin Oncol. 2012;30(3):268–73.
    1. Yoshida K, Kodera Y, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. Addition of Docetaxel to Oral Fluoropyrimidine Improves Efficacy in Patients With Stage III Gastric Cancer: Interim Analysis of JACCRO GC‐07, a Randomized Controlled Trial. J Clin Oncol. 2019;37(15):1296–1304.
    1. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T, et al. Five‐year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S‐1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol. 2011;29(33):4387–93.
    1. Kodera Y, Yoshida K, Kochi M, Ichikawa W, Kakeji Y, Sano T, et al. A randomized phase III study comparing S‐1 plus docetaxel with S‐1 alone as a postoperative adjuvant chemotherapy for curatively resected stage III gastric cancer (JACCRO GC‐07 trial). J Clin Oncol. 2018;36(15):4007.
    1. Ji J, Shen L, Li Z, Zhang X, Liang H, Xue Y, et al. Perioperative Chemotherapy of Oxaliplatin Combined with S‐1 (SOX) versus Postoperative Chemotherapy of SOX or Oxaliplatin with Capecitabine (XELOX) in Locally Advanced Gastric Adenocarcinoma with D2 Gastrectomy: a Randomized Phase III Trial (RESOLVE Trial). Ann Oncol. 2019;30(5):v851–v934. 101093/annonc/mdz394 2019.
    1. Park SH, Zang DY, Han B, Ji JH, Kim TG, Oh SY, et al. ARTIST 2: Interim results of a phase III trial involving adjuvant chemotherapy and/or chemoradiotherapy after D2‐gastrectomy in stage II/III gastric cancer (GC). J Clin Oncol. 2019;37(15):4001.
    1. Wang ZX, Li GX, Zhou ZW, Huang ZP, Wang F, Xu RH. Validation of a nomogram for selecting patients for chemotherapy after D2 gastrectomy for cancer. Br J Surg. 2017;104(9):1226–34.
    1. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345(10):725–30.
    1. Stiekema J, Trip AK, Jansen EP, Boot H, Cats A, Ponz OB, et al. The prognostic significance of an R1 resection in gastric cancer patients treated with adjuvant chemoradiotherapy. Ann Surg Oncol. 2014;21(4):1107–14.
    1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant Chemotherapy for Gastric Cancer with S‐1, an Oral Fluoropyrimidine. N Engl J Med. 2007;357(18):1810–20.
    1. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355(1):11–20.
    1. D'Ugo D, Rausei S, Biondi A, Persiani R. Preoperative treatment and surgery in gastric cancer: friends or foes? Lancet Oncol. 2009;10(2):191–5.
    1. Kim YW, Kim MJ, Ryu KW, Lim HS, Lee JH, Kong SY, et al. A phase II study of perioperative S‐1 combined with weekly docetaxel in patients with locally advanced gastric carcinoma: clinical outcomes and clinicopathological and pharmacogenetic predictors for survival. Gastric Cancer. 2016;19(2):586–96.
    1. Wang X, Zhao L, Liu H, Zhong D, Liu W, Shan G, et al. A phase II study of a modified FOLFOX6 regimen as neoadjuvant chemotherapy for locally advanced gastric cancer. Br J Cancer. 2016;114(12):1326–33.
    1. Kang YK, Yook JH, Park YK, Kim YW, Kim J, Ryu MH, et al. LBA41 ‐ Phase III randomized study of neoadjuvant chemotherapy (CT) with docetaxel(D), oxaliplatin(O) and S‐1(S) (DOS) followed by surgery and adjuvant S‐1, vs surgery and adjuvant S‐1, for resectable advanced gastric cancer (GC) (PRODIGY). Ann Oncol. 2019;30:v876–v877.
    1. Sumpter K, Harper‐Wynne C, Cunningham D, Rao S, Tebbutt N, Norman AR, et al. Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF. Br J Cancer. 2005;92(11):1976–83.
    1. Li ZY, Koh CE, Bu ZD, Wu AW, Zhang LH, Wu XJ, et al. Neoadjuvant chemotherapy with FOLFOX: improved outcomes in Chinese patients with locally advanced gastric cancer. J Surg Oncol. 2012;105(8):793–9.
    1. Kochi M, Fujii M, Kanamori N, Mihara Y, Funada T, Tamegai H, et al. Phase II Study of Neoadjuvant Chemotherapy With S‐1 and CDDP in Patients With Lymph Node Metastatic Stage II or III Gastric Cancer. Am J Clin Oncol. 2017;40(1):17–21.
    1. Li T, Chen L. Efficacy and safety of SOX regimen as neoadjuvant chemotherapy for advanced gastric cancer (Chinese). Zhonghua Wei Chang Wai Ke Za Zhi. 2011;14(2):104–6.
    1. Al‐Batran S‐E, Homann N, Schmalenberg H, Kopp H‐G, Haag GM, Luley KB, et al. Perioperative chemotherapy with docetaxel, oxaliplatin, and fluorouracil/leucovorin (FLOT) versus epirubicin, cisplatin, and fluorouracil or capecitabine (ECF/ECX) for resectable gastric or gastroesophageal junction (GEJ) adenocarcinoma (FLOT4‐AIO): A multicenter, randomized phase 3 trial. J Clin Oncol. 2017;35(15):4004.
    1. Cats A, Jansen EPM, van Grieken NCT, Sikorska K, Lind P, Nordsmark M, Meershoek‐Klein Kranenbarg E, et al. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): an international, open‐label, randomised phase 3 trial. Lancet Oncol. 2018;19(5):616–28.
    1. Mita K, Ito H, Katsube T, Tsuboi A, Yamazaki N, Asakawa H, et al. Prognostic Factors Affecting Survival After Multivisceral Resection in Patients with Clinical T4b Gastric Cancer. J Gastrointest Surg. 2017;21(12):1993–9.
    1. Roberts P, Seevaratnam R, Cardoso R, Law C, Helyer L, Coburn N. Systematic review of pancreaticoduodenectomy for locally advanced gastric cancer. Gastric Cancer. 2012;15(1):S108–115.
    1. Xiao L, Li M, Xu F, Ye H, Wu W, Long S, et al. Extended multi‐organ resection for cT4 gastric carcinoma: A retrospective analysis. Pak J Med Sci. 2013;29(2):581–5.
    1. Pietrantonio F, Miceli R, Raimondi A, Kim YW, Kang WK, Langley RE, et al. Individual Patient Data Meta‐Analysis of the Value of Microsatellite Instability As a Biomarker in Gastric Cancer. J Clin Oncol. 2019;37(35):3392–3400.
    1. Bajetta E, Floriani I, Di Bartolomeo M, Labianca R, Falcone A, Di Costanzo F, et al. Randomized trial on adjuvant treatment with FOLFIRI followed by docetaxel and cisplatin versus 5‐fluorouracil and folinic acid for radically resected gastric cancer. Ann Oncol. 2014;25(7):1373–8.
    1. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera‐Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27(6):851–6.
    1. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24(24):3953–8.
    1. Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer. 2015;15:532.
    1. Slagter AE, Jansen EPM, van Laarhoven HWM, van Sandick JW, van Grieken NCT, Sikorska K, et al. CRITICS‐II: a multicentre randomised phase II trial of neo‐adjuvant chemotherapy followed by surgery versus neo‐adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo‐adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer. 2018;18(1):877.
    1. Neoadjuvant Chemoradiotherapy vs. Chemotherapy With Radical Gastrectomy and Adjuvant Chemotherapy for Advanced Gastric Cancer (Neo‐CRAG) ( Identifier: NCT01815853). . In.
    1. Li T, Chen L.: Randomized, multicenter, controlled evaluation of S‐1 and oxaliplatin (SOX regimen) as neoadjuvant chemotherapy for advanced gastric cancer patients (RESONANCE trial). J Clin Oncol. 2014;32(3):90.
    1. Wang Y, Cheng X, Cui YH, Hou J, Ji Y, Sun YH, et al. Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis. BMC Cancer. 2018;18(1):702.
    1. Sarela AI, Lefkowitz R, Brennan MF, Karpeh MS. Selection of patients with gastric adenocarcinoma for laparoscopic staging. Am J Surg. 2006;191(1):134–38.
    1. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol. 2011;29(13):1715–21.
    1. Petrelli F, Ghidini M, Barni S, Sgroi G, Passalacqua R, Tomasello G.Neoadjuvant chemoradiotherapy or chemotherapy for gastroesophageal junction adenocarcinoma: A systematic review and meta‐analysis. Gastric Cancer. 2019;22(2):245.
    1. van Hagen P, Hulshof MC, van Lanschot JJ, Steyerberg EW, van Berge Henegouwen MI, Wijnhoven BP, et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N Engl J Med. 2012;366(22):2074–84.
    1. Tepper J, Krasna MJ, Niedzwiecki D, Hollis D, Reed CE, Goldberg R, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26(7):1086–92.
    1. Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, et al. Oxaliplatin in combination with protracted‐infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. J Clin Oncol. 2002;20(12):2844–50.
    1. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel‐based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol. 2005;23(6):1237–44.
    1. Hu JB, Sun XN, Gu BX, Wang Q, Hu WX. Effect of intensity modulated radiotherapy combined with s‐1‐based chemotherapy in locally advanced gastric cancer patients. Oncol Res Treat. 2014;37(1‐2):11–6.
    1. Inoue T, Yachida S, Usuki H, Kimura T, Hagiike M, Okano K, et al. Pilot feasibility study of neoadjuvant chemoradiotherapy with S‐1 in patients with locally advanced gastric cancer featuring adjacent tissue invasion or JGCA bulky N2 lymph node metastases. Ann Surg Oncol. 2012;19(9):2937–45.
    1. Wang X, Zhao DB, Jin J, Chi Y, Yang L, Tang Y, et al. A Randomized Phase II Trial of Neoadjuvant Chemotherapy Compared With Chemoradiation Therapy in Locally Advanced Gastroesophageal and Gastric Adenocarcinoma: Preliminary Results. Int J Radiat Oncol Biol Phys. 2016;96(2):S32.
    1. Wang X, Zhao DB, Yang L, Chi Y, Tang Y, Li N, et al. S‐1 chemotherapy and intensity‐modulated radiotherapy after D1/D2 lymph node dissection in patients with node‐positive gastric cancer: a phase I/II study. Br J Cancer. 2018;118(3):338–43.
    1. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi‐institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol. 2004;22(14):2774–80.
    1. A comparison of combination chemotherapy and combined modality therapy for locally advanced gastric carcinoma. Gastrointestinal Tumor Study Group. Cancer. 1982;49(9):1771–7.
    1. Gunderson LL, Hoskins RB, Cohen AC, Kaufman S, Wood WC, Carey RW. Combined modality treatment of gastric cancer. Int J Radiat Oncol Biol Phys. 1983;9(7):965–75.
    1. Li R, Hou WH, Chao J, Woo Y, Glaser S, Amini A, et al. Chemoradiation Improves Survival Compared With Chemotherapy Alone in Unresected Nonmetastatic Gastric Cancer. J Natl Compr Canc Netw 2018;16(8):950–58.
    1. Mizrak Kaya D, Nogueras‐Gonzáles GM, Harada K, Amlashi FG, Thomas I, Rogers JE, et al. Potentially curable gastric adenocarcinoma treated without surgery. Eur J Cancer. 2018;98:23–9.
    1. Moertel CG, ChildsDS, Jr., Reitemeier RJ, ColbyMY, Jr., Holbrook MA. Combined 5‐fluorouracil and supervoltage radiation therapy of locally unresectable gastrointestinal cancer. Lancet. 1969;2(7626):865–7.
    1. Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE. Chemotherapy in advanced gastric cancer: a systematic review and meta‐analysis based on aggregate data. J Clin Oncol. 2006;24(18):2903–9.
    1. Al‐Batran SE, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, et al. Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internistische Onkologie. J Clin Oncol. 2008;26(9):1435–42.
    1. Hiramoto S, Kikuchi A, Tetsuso H, Yoshioka A, Kohigashi Y, Maeda I. Efficacy of palliative radiotherapy and chemo‐radiotherapy for unresectable gastric cancer demonstrating bleeding and obstruction. Int J Clin Oncol. 2018;23(6):1090–4.
    1. Coia LR, Paul AR, Engstrom PF. Combined radiation and chemotherapy as primary management of adenocarcinoma of the esophagus and gastroesophageal junction. Cancer. 1988;61(4):643–9.
    1. Kim MM, Rana V, Janjan NA, Das P, Phan AT, Delclos ME, et al. Clinical benefit of palliative radiation therapy in advanced gastric cancer. Acta Oncol. 2008;47(3):421–7.
    1. Minn AY, Hsu A, La T, Kunz P, Fisher GA, Ford JM, et al. Comparison of intensity‐modulated radiotherapy and 3‐dimensional conformal radiotherapy as adjuvant therapy for gastric cancer. Cancer. 2010;116(16):3943–52.
    1. Wang X, Li G, Zhang Y, Bai S, Xu F, Wei Y, Gong Y. Single‐arc volumetric‐modulated arc therapy (sVMAT) as adjuvant treatment for gastric cancer: dosimetric comparisons with three‐dimensional conformal radiotherapy (3D‐CRT) and intensity‐modulated radiotherapy (IMRT). Med Dosim. 2013;38(4):395–400.
    1. Kang YK, Kang WK, Shin DB, Chen J, Xiong J, Wang J, et al. Capecitabine/cisplatin versus 5‐fluorouracil/cisplatin as first‐line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol. 2009;20(4):666–73.
    1. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S‐1 plus cisplatin versus S‐1 alone for first‐line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9(3):215–21.
    1. Luo HY, Xu RH, Wang F, Qiu MZ, Li YH, Li FH, et al. Phase II trial of XELOX as first‐line treatment for patients with advanced gastric cancer. Chemotherapy. 2010;56(2):94–100.
    1. Lu Z, Zhang X, Liu W, Liu T, Hu B, Li W, et al. A multicenter, randomized trial comparing efficacy and safety of paclitaxel/capecitabine and cisplatin/capecitabine in advanced gastric cancer. Gastric Cancer. 2018;21(5):782–91.
    1. Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, et al. Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first‐line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol. 2006;24(31):4991–7.
    1. Wang J, Xu R, Li J, Bai Y, Liu T, Jiao S, et al. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first‐line therapy for advanced or locally recurrent gastric cancer. Gastric Cancer. 2016;19(1):234–44.
    1. Xu RH, Wang ZQ, Shen L, Wang W, Lu JW, Dai GH, et al. S‐1 plus oxaliplatin versus S‐1 plus cisplatin as first‐line treatment for advanced diffuse‐type or mixed‐type gastric/gastroesophageal junction adenocarcinoma: A randomized, phase 3 trial. J Clin Oncol. 2019;37(15):4017.
    1. Yamada Y, Higuchi K, Nishikawa K, Gotoh M, Fuse N, Sugimoto N, et al. Phase III study comparing oxaliplatin plus S‐1 with cisplatin plus S‐1 in chemotherapy‐naive patients with advanced gastric cancer. Ann Oncol. 2015;26(1):141–8.
    1. Hall PS, Swinson D, Waters JS, Wadsley J, Falk S, Roy R, et al. Optimizing chemotherapy for frail and elderly patients (pts) with advanced gastroesophageal cancer (aGOAC): The GO2 phase III trial. J Clin Oncol. 2019;37(15):4006.
    1. Lin R, Chen Y, Zhu J, Lin P, Chen W, Fang W, et al. POF (paclitaxel plus FOLFOX) versus IP PAC (intraperitoneal paclitaxel plus FOLFOX) versus FOLFOX as a first‐line treatment in advanced gastric cancer (AGC): Update from a multicenter, randomized phase II trial, FNF‐004 trial. J Clin Oncol. 2019;37(15):4035.
    1. Yamada Y, Boku N, Mizusawa J, Iwasa S, Kadowaki S, Nakayama N, et al. Docetaxel plus cisplatin and S‐1 versus cisplatin and S‐1 in patients with advanced gastric cancer (JCOG1013): an open‐label, phase 3, randomised controlled trial. Lancet Gastroenterol Hepatol. 2019;4(7):501–10.
    1. Van Cutsem E, Boni C, Tabernero J, Massuti B, Middleton G, Dane F, et al. Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study. Ann Oncol. 2015;26(1):149–56.
    1. He MM, Zhang DS, Wang F, Wang ZX, Yuan SQ, Wang ZQ, et al. Phase II trial of S‐1 plus leucovorin in patients with advanced gastric cancer and clinical prediction by S‐1 pharmacogenetic pathway. Cancer Chemother Pharmacol. 2017;79(1):69–79.
    1. Zhou CF, Ma T, Su Y, Ye ZB, Ji J, Yu YY, et al. UGT1A1 gene polymorphisms and the toxicities of FOLFIRI in Chinese Han patients with gastrointestinal cancer. Anticancer Agents Med Chem. 2013;13(2):235–41.
    1. Hwang IG, Ji JH, Kang JH, Lee HR, Lee HY, Chi KC, et al. A multi‐center, open‐label, randomized phase III trial of first‐line chemotherapy with capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer. J Geriatr Oncol. 2017;8(3):170–5.
    1. Hall PS, Lord SR, Collinson M, Marshall H, Jones M, Lowe C, et al.: A randomised phase II trial and feasibility study of palliative chemotherapy in frail or elderly patients with advanced gastroesophageal cancer (321GO). Br J Cancer. 2017;116(4):472.
    1. Hawkes E, Okines AF, Papamichael D, Rao S, Ashley S, Charalambous H, et al. Docetaxel and irinotecan as second‐line therapy for advanced oesophagogastric cancer. Eur J Cancer. 2011;47(8):1146–51.
    1. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T, et al. Randomized, open‐label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol. 2013;31(35):4438–44.
    1. Shitara K, Takashima A, Fujitani K, Koeda K, Hara H, Nakayama N, et al. Nab‐paclitaxel versus solvent‐based paclitaxel in patients with previously treated advanced gastric cancer (ABSOLUTE): an open‐label, randomised, non‐inferiority, phase 3 trial. Lancet Gastroenterol Hepatol. 2017;2(4):277–87.
    1. Li Q, Jiang H, Li H, Xu R, Shen L, Yu Y, et al. Efficacy of trastuzumab beyond progression in HER2 positive advanced gastric cancer: a multicenter prospective observational cohort study. Oncotarget. 2016;7(31):50656–65.
    1. Nishikawa K, Takahashi T, Takaishi H, Miki A, Noshiro H, Yoshikawa T, et al. Phase II study of the effectiveness and safety of trastuzumab and paclitaxel for taxane‐ and trastuzumab‐naive patients with HER2‐positive, previously treated, advanced, or recurrent gastric cancer (JFMC45‐1102). Int J Cancer. 2017;140(1):188–96.
    1. Qin S, Ji J, R‐h Xu, Wang W, Tang Y, Bi F, et al. Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non‐interventional registry study (EVIDENCE). J Clin Oncol. 2019;37(15):4025.
    1. Qin S, Ji J, Xu RH, Wang W, Tang Y, Bi F, et al. Treatment patterns and outcomes in Chinese gastric cancer patients by HER2 status: a non‐interventional registry study (EVIDENCE). Oncologist. 2021.
    1. Tabernero J, Hoff PM, Shen L, Ohtsu A, Shah MA, Cheng K, et al. Pertuzumab plus trastuzumab and chemotherapy for HER2‐positive metastatic gastric or gastro‐oesophageal junction cancer (JACOB): final analysis of a double‐blind, randomised, placebo‐controlled phase 3 study. Lancet Oncol. 2018;19(10):1372–1384.
    1. Hecht JR, Bang YJ, Qin SK, Chung HC, Xu JM, Park JO, et al. Lapatinib in Combination With Capecitabine Plus Oxaliplatin in Human Epidermal Growth Factor Receptor 2‐Positive Advanced or Metastatic Gastric, Esophageal, or Gastroesophageal Adenocarcinoma: TRIO‐013/LOGiC–A Randomized Phase III Trial. J Clin Oncol. 2016;34(5):443–51.
    1. Satoh T, Xu RH, Chung HC, Sun GP, Doi T, Xu JM, et al. Lapatinib plus paclitaxel versus paclitaxel alone in the second‐line treatment of HER2‐amplified advanced gastric cancer in Asian populations: TyTAN–a randomized, phase III study. J Clin Oncol. 2014;32(19):2039–49.
    1. Kang Y‐K, Shah MA, Ohtsu A, Cutsem EV, Ajani JA, Tvd Horst, et al. Thuss‐Patience PC: A randomized, open‐label, multicenter, adaptive phase 2/3 study of trastuzumab emtansine (T‐DM1) versus a taxane (TAX) in patients (pts) with previously treated HER2‐positive locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma (LA/MGC/GEJC). J Clin Oncol. 2016;34(4):5.
    1. Fuchs CS, Tomasek J, Yong CJ, Dumitru F, Passalacqua R, Goswami C, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro‐oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo‐controlled, phase 3 trial. Lancet. 2014;383(9911):31–9.
    1. Wilke H, Muro K, Van Cutsem E, Oh SC, Bodoky G, Shimada Y, et al. Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro‐oesophageal junction adenocarcinoma (RAINBOW): a double‐blind, randomised phase 3 trial. Lancet Oncol. 2014;15(11):1224–35.
    1. Li J, Qin S, Xu J, Xiong J, Wu C, Bai Y, et al. Randomized, Double‐Blind, Placebo‐Controlled Phase III Trial of Apatinib in Patients With Chemotherapy‐Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. J Clin Oncol. 2016;34(13):1448–54.
    1. Qin SK, Li J. Expert Committe Consensus. Clinical application of apatinib in the treatment of gastric cancer (Chinese). Linchuang Zhongliuxue Zazhi. 2015;000(009):841–7.
    1. Kang YK, Boku N, Satoh T, Ryu MH, Chao Y, Kato K, et al. Nivolumab in patients with advanced gastric or gastro‐oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO‐4538‐12, ATTRACTION‐2): a randomised, double‐blind, placebo‐controlled, phase 3 trial. Lancet. 2017;390(10111):2461–71.
    1. Boku N, Satoh T, Ryu MH, Chao Y, Kato K, Chung HC, et al. Nivolumab in previously treated advanced gastric cancer (ATTRACTION‐2): 3‐year update and outcome of treatment beyond progression with nivolumab. Gastric Cancer. 2021.
    1. Fuchs CS, Doi T, Jang RW, Muro K, Satoh T, Machado M, et al. Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer: Phase 2 Clinical KEYNOTE‐059 Trial. JAMA Oncol. 2018;4(5):e180013.
    1. Le DT, Durham JN, Smith KN, Wang H, Bartlett BR, Aulakh LK, et al. Mismatch repair deficiency predicts response of solid tumors to PD‐1 blockade. Science. 2017;357(6349):409–13.
    1. Shitara K, Van Cutsem E, Bang YJ, Fuchs C, Wyrwicz L, Lee KW, et al. Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First‐line, Advanced Gastric Cancer: The KEYNOTE‐062 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2020;6(10):1571–80.
    1. Moehler M, Shitara K, Garrido M, Salman P, Shen L, Wyrwicz L, et al. LBA6_PR ‐ Nivolumab (nivo) plus chemotherapy (chemo) versus chemo as first‐line (1L) treatment for advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC)/esophageal adenocarcinoma (EAC): First results of the CheckMate 649 study. Ann Oncol. 2020;31(4):S1142‐S1215. 10.1016/annonc/annonc325
    1. Boku N, Ryu MH, Oh DY, Oh SC, Chung HC, Lee KW, et al. LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION‐4 (ONO‐4538‐37) study. Ann Oncol. 2020;31:S1192.
    1. Wang F, Wei XL, Wang FH, Xu N, Shen L, Dai GH, et al. Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo‐refractory gastric cancer treated with toripalimab, a PD‐1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019;30(9):1479–86.
    1. Kim ST, Cristescu R. Comprehensive molecular characterization of clinical responses to PD‐1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449–58.
    1. Qiu MZ, He CY, Yang DJ, Zhou DL, Zhao BW, Wang XJ, et al. Observational cohort study of clinical outcome in Epstein‐Barr virus associated gastric cancer patients. Ther Adv Med Oncol. 2020;12:1758835920937434.
    1. Xie T, Liu Y, Zhang Z, Zhang X, Gong J, Qi C, et al. Positive Status of Epstein‐Barr Virus as a Biomarker for Gastric Cancer Immunotherapy: A Prospective Observational Study. J Immunother. 2020;43(4):139–44.
    1. Janjigian YY, Maron SB, Chatila WK, Millang B, Chavan SS, Alterman C, et al. First‐line pembrolizumab and trastuzumab in HER2‐positive oesophageal, gastric, or gastro‐oesophageal junction cancer: an open‐label, single‐arm, phase 2 trial. Lancet Oncol. 2020;21(6):821–31.
    1. Shen L, Peng Z, Zhang YQ, et al. Camrelizumab combined with capecitabine and oxaliplatin followed by camrelizumab and apatinib as first‐line therapy for advanced or metastatic gastric or gastroesophageal junction cancer: updated results from a multicenter, open label phase II trial [abstract no. 4031]. J Clin Oncol. 2019;37(15).
    1. Leake PA, Cardoso R, Seevaratnam R, Lourenco L, Helyer L, Mahar A, et al. A systematic review of the accuracy and utility of peritoneal cytology in patients with gastric cancer. Gastric Cancer. 2012;15(1):S27–37.
    1. Jamel S, Markar SR, Malietzis G, Acharya A, Athanasiou T, Hanna GB. Prognostic significance of peritoneal lavage cytology in staging gastric cancer: systematic review and meta‐analysis. Gastric Cancer. 2018;21(1):10–18.
    1. Coccolini F, Catena F, Glehen O, Yonemura Y, Sugarbaker PH, Piso P, et al. Effect of intraperitoneal chemotherapy and peritoneal lavage in positive peritoneal cytology in gastric cancer. Systematic review and meta‐analysis. Eur J Surg Oncol. 2016;42(9):1261–67.
    1. Lopez‐Basave HN, Quiroz‐Sandoval OA, Padilla‐Rosciano AE, Leon‐Takahashi AM, Miranda‐Devora G, Arrollo‐Monroy A. Role of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Cir Cir. 2018;86(3):277–84.
    1. Kodera Y, Ito S, Mochizuki Y, Ohashi N, Tanaka C, Kobayashi D, et al. Long‐term follow up of patients who were positive for peritoneal lavage cytology: final report from the CCOG0301 study. Gastric Cancer. 2012;15(3):335–37.
    1. Kano K, Aoyama T, Maezawa Y, Nakajima T, Ikeda K, Yamada T, et al. The survival and prognosticators of peritoneal cytology‐positive gastric cancer patients who received upfront gastrectomy and subsequent S‐1 chemotherapy. Int J Clin Oncol. 2017;22(5):887–96.
    1. Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta‐analysis of randomized trials. Eur J Surg Oncol. 2014;40(1):12–26.
    1. Yamaguchi H, Kitayama J, Ishigami H, Emoto S, Yamashita H, Watanabe T. A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S‐1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer. 2013;119(18):3354–8.
    1. Yoshida K, Yamaguchi K, Okumura N, Tanahashi T, Kodera Y. Is conversion therapy possible in stage IV gastric cancer: the proposal of new biological categories of classification. Gastric Cancer. 2016;19(2):329–38.
    1. Ishigami H, Fujiwara Y, Fukushima R, Nashimoto A, Yabusaki H, Imano M, et al. Phase III Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S‐1 Versus Cisplatin Plus S‐1 in Patients With Gastric Cancer With Peritoneal Metastasis: PHOENIX‐GC Trial. J Clin Oncol. 2018;36(19):1922–9.
    1. Niibe Y, Hayakawa K. Oligometastases and oligo‐recurrence: the new era of cancer therapy. Jpn J Clin Oncol. 2010;40(2):107–111.
    1. Milano MT, Katz AW, Zhang H, Okunieff P. Oligometastases treated with stereotactic body radiotherapy: long‐term follow‐up of prospective study. Int J Radiat Oncol Biol Phys. 2012;83(3):878–86.
    1. Hellman S, Weichselbaum RR. Oligometastases. J Clin Oncol. 1995;13(1):8–10.
    1. Badgwell B, Cormier JN, Xing Y, Yao J, Bose D, Krishnan S, et al. Attempted salvage resection for recurrent gastric or gastroesophageal cancer. Ann Surg Oncol. 2009;16(1):42–50.
    1. Ishido K, Higuchi K, Tanabe S, Azuma M, Sasaki T, Katada C, et al. Chemoradiotherapy for patients with recurrent lymph‐node metastasis or local recurrence of gastric cancer after curative gastrectomy. Jpn J Radiol. 2016;34(1):35–42.
    1. Xu C, Xie J, Liang N, Wang J, Qiao L, Luo H, et al. Concurrent involved‐field radiotherapy and XELOX in gastric cancer patients with postoperative oligometastatic recurrence. Journal of Cancer Research and Therapeutics. 2014;10(8):267–71.
    1. Maruyama K, Kaminishi M, Hayashi K, Isobe Y, Honda I, Katai H, et al. Japanese Gastric Cancer Association Registration Committee. Gastric cancer treated in 1991 in Japan: data analysis of nationwide registry. Gastric Cancer. 2006;9(2):51–66.
    1. Ohira M, Toyokawa T, Sakurai K, Kubo N, Tanaka H, Muguruma K, et al. Current status in remnant gastric cancer after distal gastrectomy. World J Gastroenterol. 2016;22(8):2424–33.
    1. Japanese Gastric Cancer Association . Japanese classification of gastric carcinoma (Japanese), 13 edn: JinYuan; 1999.
    1. Sano T, Sasako M, Yamamoto S, Nashimoto A, Kurita A, Hiratsuka M, et al. Gastric cancer surgery: morbidity and mortality results from a prospective randomized controlled trial comparing D2 and extended para‐aortic lymphadenectomy–Japan Clinical Oncology Group study 9501. J Clin Oncol. 2004;22(14):2767–73.
    1. Fujitani K, Yang HK, Mizusawa J, Kim YW, Terashima M, Han SU, et al. Gastrectomy plus chemotherapy versus chemotherapy alone for advanced gastric cancer with a single non‐curable factor (REGATTA): a phase 3, randomised controlled trial. Lancet Oncol. 2016;17(3):309–18.
    1. Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K, et al. Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009;96(9):1015–22.
    1. Tsuburaya A, Mizusawa J, Tanaka Y, Fukushima N, Nashimoto A, Sasako M. Stomach Cancer Study Group of the Japan Clinical Oncology G: Neoadjuvant chemotherapy with S‐1 and cisplatin followed by D2 gastrectomy with para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis. Br J Surg. 2014;101(6):653–60.
    1. Ito S, Sano T, Mizusawa J, Takahari D, Katayama H, Katai H, et al. A phase II study of preoperative chemotherapy with docetaxel, cisplatin, and S‐1 followed by gastrectomy with D2 plus para‐aortic lymph node dissection for gastric cancer with extensive lymph node metastasis: JCOG1002. Gastric Cancer. 2017;20(2):322–31.
    1. Katayama H, Tsuburaya A, Mizusawa J, Nakamura K, Katai H, Imamura H, et al. An integrated analysis of two phase II trials (JCOG0001 and JCOG0405) of preoperative chemotherapy followed by D3 gastrectomy for gastric cancer with extensive lymph node metastasis. Gastric Cancer. 2019;22(6):1301–7.
    1. Wang Y, Yu YY, Li W, Feng Y, Hou J, Ji Y, et al. A phase II trial of Xeloda and oxaliplatin (XELOX) neo‐adjuvant chemotherapy followed by surgery for advanced gastric cancer patients with para‐aortic lymph node metastasis. Cancer Chemother Pharmacol. 2014;73(6):1155–61.
    1. Thelen A, Jonas S, Benckert C, Lopez‐Hanninen E, Neumann U, Rudolph B, et al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008;34(12):1328–34.
    1. Li W, Jiang H, Yu Y, Wang Y, Wang Z, Cui Y, et al. Outcomes of gastrectomy following upfront chemotherapy in advanced gastric cancer patients with a single noncurable factor: a cohort study. Cancer Manag Res. 2019;11:2007–13.
    1. Liao YY, Peng NF, Long D, Yu PC, Zhang S, Zhong JH, Li LQ. Hepatectomy for liver metastases from gastric cancer: a systematic review. BMC Surg. 2017;17(1):14.
    1. Gavriilidis P, Roberts KJ, de'Angelis N, Sutcliffe RP. Gastrectomy Alone or in Combination With Hepatic Resection in the Management of Liver Metastases From Gastric Cancer: A Systematic Review Using an Updated and Cumulative Meta‐Analysis. J Clin Med Res. 2019;11(8):600–8.
    1. Markar SR, Mikhail S, Malietzis G, Athanasiou T, Mariette C, Sasako M, Hanna GB. Influence of Surgical Resection of Hepatic Metastases From Gastric Adenocarcinoma on Long‐term Survival: Systematic Review and Pooled Analysis. Ann Surg. 2016;263(6):1092–1101.
    1. Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R, et al. Long‐term survival after liver metastasectomy in gastric cancer: Systematic review and meta‐analysis of prognostic factors. Cancer Treat Rev. 2018;69:11–20.
    1. Kataoka K, Kinoshita T, Moehler M, Mauer M, Shitara K, Wagner AD, et al. Current management of liver metastases from gastric cancer: what is common practice? New challenge of EORTC and JCOG. Gastric Cancer. 2017;20(5):904–12.
    1. Guner A, Son T, Cho I, Kwon IG, An JY, Kim HI, Cheong JH, Noh SH, Hyung WJ: Liver‐directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016;19(3):951–60.
    1. Zhou F, Yu XL, Liang P, Cheng Z, Han ZY, Yu J, et al. Microwave ablation is effective against liver metastases from gastric adenocarcinoma. Int J Hyperthermia. 2017;33(7):830–5.
    1. Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Takahashi T, Uji M, Kumada T. Adjuvant hepatic artery infusion chemotherapy after hemihepatectomy for gastric cancer liver metastases. Int J Surg. 2017;46:79–84.
    1. Liu SF, Lu CR, Cheng HD, Xi HQ, Cui JX, Li JY, et al. Comparison of Therapeutic Efficacy between Gastrectomy with Transarterial Chemoembolization Plus Systemic Chemotherapy and Systemic Chemotherapy Alone in Gastric Cancer with Synchronous Liver Metastasis. Chin Med J. 2015;128(16):2194–2201.
    1. Goodman KA, Wiegner EA, Maturen KE, Zhang Z, Mo Q, Yang G, et al. Dose‐escalation study of single‐fraction stereotactic body radiotherapy for liver malignancies. Int J Radiat Oncol Biol Phys. 2010;78(2):486–93.
    1. Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19(3):968–76.
    1. Tang K, Liu Y, Dong L, Zhang B, Wang L, Chen J, et al. Influence of thermal ablation of hepatic metastases from gastric adenocarcinoma on long‐term survival: Systematic review and pooled analysis. Medicine (Baltimore). 2018;97(49):e13525.
    1. Brieau B, Auzolle C, Pozet A, Tougeron D, Bouche O, Soibinet P, et al. Efficacy of modern chemotherapy and prognostic factors in patients with ovarian metastases from gastric cancer: A retrospective AGEO multicentre study. Dig Liver Dis. 2016;48(4):441–45.
    1. Cho JH, Lim JY, Choi AR, Choi SM, Kim JW, Choi SH, Cho JY. Comparison of Surgery Plus Chemotherapy and Palliative Chemotherapy Alone for Advanced Gastric Cancer with Krukenberg Tumor. Cancer Res Treat. 2015;47(4):697–705.
    1. Yan D, Du Y, Dai G, Huang L, Xu Q, Yu P. Management Of Synchronous Krukenberg Tumors From Gastric Cancer: a Single‐center Experience. J Cancer. 2018;9(22):4197–4203.
    1. Shinohara T, Maeda Y, Hamada T, Futakawa N. Survival benefit of surgical treatment for liver metastases from gastric cancer. J Gastrointest Surg. 2015;19(6):1043–51.
    1. Cui JK, Liu M, Shang XK. Hepatectomy for Liver Metastasis of Gastric Cancer: A Meta‐Analysis. Surg Innov. 2019;26(6):692–7.
    1. Hwang JE, Kim SH, Jin J, Hong JY, Kim MJ, Jung SH, et al. Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2014;31(1):25–32.
    1. Aurello P, Berardi G, Antolino L, Antonelli G, Rampini A, Moschetta G, Ramacciato G. Is a Surgical Approach Justified in Metachronous Krukenberg Tumor from Gastric Cancer? A Systematic Review. Oncol Res Treat. 2018;41(10):644–9.
    1. Rosa F, Marrelli D, Morgagni P, Cipollari C, Vittimberga G, Framarini M, et al. Krukenberg Tumors of Gastric Origin: The Rationale of Surgical Resection and Perioperative Treatments in a Multicenter Western Experience. World J Surg. 2016;40(4):921–28.
    1. Guo ZQ, Yu JM, Li W, Fu ZM, Lin Y, Shi YY, et al. Survey and analysis of the nutritional status in hospitalized patients with malignant gastric tumors and its influence on the quality of life. Support Care Cancer. 2020;28(1):373–80.
    1. Lu Z, Fang Y, Liu C, Zhang X, Xin X, He Y, et al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase III Randomized Controlled Trial. J Clin Oncol. 2021;39(7):748–56.
    1. Guidelines Committee of the Chinese Society of Clinical Oncology . Chinese Society of Clinical Oncology (CSCO) guidelines for nutritional therapy in patients with malignant tumor. Beijing: People's Medical Publishing House, 2019.
    1. Gastric Cancer Committee of the China Anti‐Cancer Association Committee and the Gastrointestinal Surgery Committee of the Chinese Society of Surgery . Chinese Expert Consensus on the perioperative nutritional therapy for gastric cancer (2019 Edition). Zhongguo Shiyong Waike Zazhi. 2020;40(2): 145–51.
    1. Kondrup J, Rasmussen HH, Hamberg O, Stanga Z. Nutritional risk screening (NRS 2002): a new method based on an analysis of controlled clinical trials. Clin Nutr. 2003;2(3):321–36.
    1. Bauer J, Capra S, Ferguson M. Use of the scored Patient‐Generated Subjective Global Assessment (PG‐SGA) as a nutrition assessment tool in patients with cancer. Eur J Clin Nutr. 2002;56(8):779–85.
    1. Mortensen K, Nilsson M, Slim K, Schäfer M, Mariette C, Braga M, et al. Consensus guidelines for enhanced recovery after gastrectomy: Enhanced Recovery After Surgery (ERAS®) Society recommendations. Br J Surg. 2014;101(10):1209–29.
    1. Shi H, Xu H, Li S, Cao W, Li W, Ba Y, et al. The 5‐step principle for the treatment of malnutrition. Zhongliu Daixie yu Yingyang Dianzi Zazhi. 2015;000(001):29–33.
    1. Shi HP, Li SY, Wang KH, Wu XT, Li Y, Zhao QC, et al. Guidelines for nutritional therapy in patients with gastric cancer (Chinese). Zhongliu Daixie yu Yingyang Dianzi Zazhi. 2015; (02):488–91.
    1. Kim YI, Choi IJ.Endoscopic management of tumor bleeding from inoperable gastric cancer. Clin Endosc. 2015;48(2):121–27.
    1. Chen Y, Yang Y, Xu WJ, Xin YJ, Wang YN, Zhou X, Li X. Clinical application of interventional embolization in tumor‐associated hemorrhage. Ann Transl Med. 2020;8(6):394.
    1. Bian SB, Shen WS, Xi HQ, Wei B, Chen L: Palliative Therapy for Gastric Outlet Obstruction Caused by Unresectable Gastric Cancer: A Meta‐analysis Comparison of Gastrojejunostomy with Endoscopic Stenting. Chin Med J. 2016;129(9):1113–21.
    1. Liu H, Xu Q, Ma FH, Marshal M, Li Y, Li WK, Tian YT. Clinical results of total laparoscopic partial gastrectomy for gastric cancer with pyloric obstruction. Zhonghua Zhongliu Zazhi. 2020;42(06):445–48.
    1. Smyth EC, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D, Committee EG. Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up. Ann Oncol. 2016;27(5):v38–v49.
    1. Association Japanese Gastric Cancer . Japanese Classifcation of Gastric Carcinoma (Japanese). 15th ed. Tokyo: Kanehara Shuppan; 2017.
    1. Japanese Gastric Cancer A . Japanese gastric cancer treatment guidelines 2014 (ver. 4). Gastric Cancer. 2017;20(1):1‐19.
    1. Blair VR, McLeod M, Carneiro F, Coit DG, D'Addario JL, van Dieren JM, et al. Hereditary diffuse gastric cancer: updated clinical practice guidelines. Lancet Oncol. 2020;21(8):e386‐e397.
    1. Pharoah PD, Guilford P, Caldas C. International Gastric Cancer Linkage C: Incidence of gastric cancer and breast cancer in CDH1 (E‐cadherin) mutation carriers from hereditary diffuse gastric cancer families. Gastroenterology. 2001;121(6):1348–53.
    1. Majewski IJ, Kluijt I, Cats A, Scerri TS, de Jong D, Kluin RJ, et al. An alpha‐E‐catenin (CTNNA1) mutation in hereditary diffuse gastric cancer. J Pathol. 2013;229(4):621–29.
    1. Kluijt I, Sijmons RH, Hoogerbrugge N, Plukker JT, de Jong D, van Krieken JH, et al. Familial gastric cancer: guidelines for diagnosis, treatment and periodic surveillance. Fam Cancer. 2012;11(3):363–9.
    1. van der Post RS, Vogelaar IP, Carneiro F, Guilford P, Huntsman D, Hoogerbrugge N, et al. Hereditary diffuse gastric cancer: updated clinical guidelines with an emphasis on germline CDH1 mutation carriers. J Med Genet. 2015;52(6):361–74.
    1. de Boer WB, Ee H, Kumarasinghe MP. Neoplastic Lesions of Gastric Adenocarcinoma and Proximal Polyposis Syndrome (GAPPS) Are Gastric Phenotype. Am J Surg Pathol. 2018;42(1):1–8.
    1. Worthley DL, Phillips KD, Wayte N, Schrader KA, Healey S, Kaurah P, et al. Gastric adenocarcinoma and proximal polyposis of the stomach (GAPPS): a new autosomal dominant syndrome. Gut. 2012;61(5):774–79.
    1. Hansford S, Kaurah P, Li‐Chang H, Woo M, Senz J, Pinheiro H, et al. Hereditary Diffuse Gastric Cancer Syndrome: CDH1 Mutations and Beyond. JAMA Oncol. 2015;1(1):23–32.
    1. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW.American College of G: ACG clinical guideline: Genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110(2):223–62; quiz 263.
    1. Capelle LG, Van Grieken NC, Lingsma HF, Steyerberg EW, Klokman WJ, Bruno MJ, et al. Risk and epidemiological time trends of gastric cancer in Lynch syndrome carriers in the Netherlands. Gastroenterology. 2010;138(2):487–92.
    1. Kim JW, Shin SS, Heo SH, Choi YD, Lim HS, Park YK, et al. Diagnostic performance of 64‐section CT using CT gastrography in preoperative T staging of gastric cancer according to 7th edition of AJCC cancer staging manual. Eur Radiol. 2012;22(3):654–62.
    1. Habermann CR, Weiss F, Riecken R, Honarpisheh H, Bohnacker S, Staedtler C, et al. Preoperative staging of gastric adenocarcinoma: comparison of helical CT and endoscopic US. Radiology. 2004;230(2):465–71.
    1. Hasegawa S, Yoshikawa T, Shirai J, Fujikawa H, Cho H, Doiuchi T, et al. A prospective validation study to diagnose serosal invasion and nodal metastases of gastric cancer by multidetector‐row CT. Ann Surg Oncol. 2013;20(6):2016–22.
    1. Kim TU, Kim S, Lee JW, Lee NK, Jeon TY, Park DY. MDCT features in the differentiation of T4a gastric cancer from less‐advanced gastric cancer: significance of the hyperattenuating serosa sign. Br J Radiol. 2013;86(1029):20130290.
    1. Lee SL, Ku YM, Jeon HM, Lee HH. Impact of the Cross‐Sectional Location of Multidetector Computed Tomography Scans on Prediction of Serosal Exposure in Patients with Advanced Gastric Cancer. Ann Surg Oncol. 2017;24(4):1003–9.
    1. You MW, Park S, Kang HJ, Lee DH, Radiologic serosal invasion sign as a new criterion of T4a gastric cancer on computed tomography: diagnostic performance and prognostic significance in patients with advanced gastric cancer. Abdom Radiol (NY). 2020;45(10):2950–9.
    1. Fukuya T, Honda H, Hayashi T, Kaneko K, Tateshi Y, Ro T, et al. Lymph‐node metastases: efficacy for detection with helical CT in patients with gastric cancer. Radiology. 1995;197(3):705–11.
    1. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer. 2009;12(1):6–22.
    1. Kumano S, Murakami T, Kim T, Hori M, Iannaccone R, Nakata S, et al. T staging of gastric cancer: role of multi‐detector row CT. Radiology. 2005;237(3):961–6.

Source: PubMed

Sponsors et collaborateurs

Les conditions médicales

Interventions en matière de drogue

3
S'abonner